The quality control theory of aging by Warren Ladiges
EDITORIAL
The quality control theory of aging
Warren Ladiges*
Department of Comparative Medicine, University of Washington, Seattle, WA, USA
The quality control (QC) theory of aging is based on the concept that aging is the result of a reduction in QC
of cellular systems designed to maintain lifelong homeostasis. Four QC systems associated with aging are
1) inadequate protein processing in a distressed endoplasmic reticulum (ER); 2) histone deacetylase (HDAC)
processing of genomic histones and gene silencing; 3) suppressed AMPK nutrient sensing with inefficient
energy utilization and excessive fat accumulation; and 4) beta-adrenergic receptor (BAR) signaling and
environmental and emotional stress. Reprogramming these systems to maintain efficiency and prevent aging
would be a rational strategy for increased lifespan and improved health. The QC theory can be tested with a
pharmacological approach using three well-known and safe, FDA-approved drugs: 1) phenyl butyric acid, a
chemical chaperone that enhances ER function and is also an HDAC inhibitor, 2) metformin, which activates
AMPK and is used to treat type 2 diabetes, and 3) propranolol, a beta blocker which inhibits BAR signaling
and is used to treat hypertension and anxiety. A critical aspect of the QC theory, then, is that aging is
associated with multiple cellular systems that can be targeted with drug combinations more effectively than
with single drugs. But more importantly, these drug combinations will effectively prevent, delay, or reverse
chronic diseases of aging that impose such a tremendous health burden on our society.
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A
practical and blue collar theory of aging can
be described as a reduction in cellular quality
control (QC) systems designed to maintain life-
long homeostasis. QC system failures associated with
aging include: 1) inadequate protein processing in a
distressed endoplasmic reticulum (ER); 2) histone deace-
tylase (HDAC) processing of genomic histones and gene
silencing; 3) suppressed AMPK nutrient sensing with
inefficient energy utilization and excessive fat accumula-
tion; and 4) beta-adrenergic receptor (BAR) signaling
and environmental and emotional stress. Reprogramming
these systems to maintain efficiency and prevent aging
would be a rational strategy for increased lifespan and
improved health.
The QC theory of aging challenges several paradigms
established over the years in an attempt to provide an
explanation for why we age. The first paradigm is that
aging is a slowly deteriorating condition that is driven
by loss of cellular function. The theory challenges this para-
digm by stating that it is a series of interactive systems
that occur as the result of a reduction in QC. Therefore,
cellular function can be targeted to overcome the lack of
QC. The second paradigm is that aging is the result of a
single genetic pathway. The QC theory challenges this
paradigm by proposing that aging is a series of genetic
system pathways that interact to promote dysfunctional
cellular activity associated with increasing age. Inherent
in this challenge is the notion that these systems can be
targeted in a pharmacological manner. The third para-
digm consists of the unilateral concept that aging is a
separate biological process unrelated to the development
of chronic diseases that are prevalent in the aging
population. The QC theory challenges this paradigm by
proposing that a multifunctional approach to delay aging
will also prevent or delay chronic diseases associated with
increasing age. It is the chronic disease aspect that weighs
heavily on the health burden of Americans and popula-
tions worldwide.
The clinical relevance to humans is that no one wants
to live longer only to be under severe suffering from co-
morbid disease conditions. Living longer should not
mean increased medical costs added on to an already
bloated medical care system in financial crises. Rather,
living longer means productive living that contributes to
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disease-free manner means more productive people that
are able to continue to make positive contributions to
society. The retirement age would be extended by decades
and more people would still be working and contributing
to social security, and less people drawing social security
checks for shorter periods of time. For example, a 20%
increase in lifespan using 86 years as an average lifespan
figure would mean an extra 17 years of life, with end
of life coming at 103 years instead of 86 years. These
additional years would be productive and relatively
disease free. A 30% increase in lifespan would mean an
additional 26 years of disease-free living.
The four systems, ER stress response, HDAC proces-
sing, AMPK nutrient sensing, and BAR signaling, are
involved in cellular activities that can influence aging and
the development of age-related diseases (Fig. 1). They
have all been shown to be responsive to pharmacological
targeting. The first of the four QC systems is protein
QC through the ER. Protein processing in the ER is
dependent on strict QC to assure newly synthesized pro-
teins are intact and functional. If the QC machinery
fails or slips a bit, proteins will be released that are less
efficient or even nonfunctional. The oxidizing environ-
ment of the ER provides ideal conditions for membrane
proteins as well as secretory proteins to fold into their
natural conformation. However, ER stress occurs when
the homeostatic environment of the ER is disrupted due
to adverse physiological conditions such as nutrient
deprivation, hypoxia, or viral infection leading to accu-
mulation of unfolded polypeptides in the ER lumen. The
majority of cells cope with the increased ER load by
activating the unfolded protein response (UPR), an
integrated signal transduction system consisting of dis-
tinct mediators such as PERK and ATF6 (1), which act
to attenuate protein translation, clear misfolded proteins
through degradation, increase ER folding capacity, and
upregulate endogenous chaperones that assist in protein
folding. An ability to mount a stress resistance under
pressure is a major host defense mechanism and has been
a fundamental force during evolution. However, the
adaptation capacity clearly declines during aging and
this loss of stress resistance accelerates the aging pro-
cess exposing the organism to degenerative diseases (2).
The effect of stress on organisms seems to be a dose-
dependent response, that is, mild stress induces a stress
tolerance and extends the lifespan whereas excessive
stress accentuates the aging process. This paradox is
known as hormesis in aging research. It is essential to
distinguish the intensity of cellular stress and thus mount
an appropriate host defense. Interestingly, ER stress
transducers can distinguish the intensity of ER stress and
induce a dose-dependent UPR, either adaptive response
to stress or apoptotic cell death. The efficiency of the
stress recognition system and UPR signaling declines
during aging.
Increasing evidence indicates that ER stress is involved
in various diseases. ER stress has been linked to condi-
tions such as hyperinsulinemia and hyperglycemia, both
of which promote adipocyte differentiation and weight
gain (3). Further, nutrient imbalance, excessive lipid
storage, and insulin resistance in adipocytes can lead to
ER stress. ER stress signaling plays an important role in
the pathogenesis of diabetes and heart disease. The latter
is a common comorbidity of diabetes and worsens patient
outcome. Results from clinical studies suggest beneficial
effects of metformin (MET), a widely used oral drug for
the treatment of type 2 diabetes, on the heart of diabetic
patients with heart failure. MET has been found to
activate ER stress but not ER-stress-induced apoptosis in
cardiomyocytes (4). In the human heart, ischemia/reper-
fusion has been correlated to ER stress, and several
markers of the UPR participate during cardiac remodel-
ing and fibrosis.
Protein misfolding in the ER is responsive to chemical
chaperone compounds such as phenylbutyric acid (PBA).
PBA is thought to act by stabilizing improperly folded
proteins, reducing protein aggregation, and enhancing
efficiency of endogenous chaperones (5). PBA has been
shown to reduce ER stress and restore glucose home-
ostasis in mice with type 2 diabetes (1,6). It also inhibits
adipogenesis by modulating the ER stress response (3),
and reduces amyloid plaques and rescues cognitive behav-
ior in Alzheimer’s disease transgenic mice (7). Increas-
ing the ER luminal folding capacity with exogenously
administrated PBA has been found to be a powerful
strategy for preventing the development of isoproterenol-
induced cardiac fibrosis and adverse remodeling (8). It
would seem that the use of the BAR blocker propranolol
(PROP) might help to accentuate these beneficial effects.
Fig. 1. The quality control theory of aging. ER stress response,
HDAC processing, AMPK nutrient sensing, and beta-adrenergic
receptor (BAR) signaling are systems involved in cellular activities
that affect aging and age-related diseases, such as dementia,
heart failure, diabetes, and cancer.
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gene silencing. HDACs are known as HDACs because
histones are the most important target. They catalyze the
deacetylation of alpha-acetyl lysine that resideswithin the
NH2-terminal tail of core histones resulting in increased
binding to chromatin and suppression of gene transcrip-
tion (9). A number of HDACs have been identified that
are now classified into at least three different classes.
Class 1 and 2 have Zn in their catalytic site and are
inhibited by trichostatin, vorinostat, and PBA. Class 3
HDACs include sirtuins, which have an absolute require-
ment for NAD, do not have Zn in their catalytic
domains, and are targeted by activators rather than
inhibitors.
Class 1 HDACs have ubiquitous expression, while class
2 HDACs are tissue specific, with highest expression in
brain, heart and muscle. In the heart, they act as signal
responsive repressors of cardiac hypertrophy. Recent
evidence indicates that different HDACs participate in
a variety of heart diseases, such as arrhythmias, heart
failure, acute coronary syndrome, and cardiac hypertro-
phy (10). First-line therapy for heart failure includes
drugs aimed at inhibiting signaling pathways elicited by
cell surface receptors such as ACE inhibitors, angiotensin
inhibitors, and BARs (beta blockers). Despite efficacy of
these drugs, the high mortality rate for patients with heart
failure justifies the need to target alternative pathogenic
mechanisms, such as HDACs. It has been shown that
broad inhibitors for Class 1 and Class 2 HDACs can
prevent cardiac hypertrophy in animal models (11). PBA
is a relatively weak broad-spectrum inhibitor of Class 1
and Class 2 HDACs, and inhibits histone deacetylation
such that gene transcription is allowed to occur with the
activation of genes associated with an overall slowing of
cell growth and proliferation (9).
It is of interest that HDAC1, HDAC2 and HDAC3,
which are Class 1, have been shown to co-immunopreci-
pitate with the ATP-dependent chaperone heat shock
protein 70 (HSP-70) involved in the ER stress response
(12). This is most likely the reason that PBA is active
as an ER stress chaperone and an HDAC inhibitor, so
it not only enhances protein folding and decreases ER
stress, but it also inhibits histone deacetylation. There-
fore, there is rationale to consider PBA as part of a treat-
ment strategy for heart disease, cancer and inflammatory
conditions associated with aging.
The third system is the AMPK nutrient sensing system.
AMPK regulates cellular metabolism. When activated by
a deficit in nutrients, AMPK stimulates glucose uptake
and lipid oxidation to produce energy, while tuning off
energy-consuming processes including glucose and lipid
production to restore energy balance (13). Disruption of
energy balance caused by over eating and a sedentary life
style has led to an increased prevalence of type 2 diabetes,
a metabolic disorder associated with insulin resistance
and suppressed AMPK activity. AMPK integrates sig-
naling circuits between peripheral tissues and the hypo-
thalamus to regulate food intake and whole body energy
expenditure. There is evidence to suggest that AMPK
mediates leptin activity to diminish adiposity by reducing
food intake and improve insulin sensitivity. AMPK also
signals to multiple pathways that regulate cell growth
and proliferation. Prominent among these is the mTOR
complex, which is blocked by activation of AMPK. mTOR
integrates signals from growth factors and nutrients to
control protein synthesis and is associated with oncogenesis
(14).
The AMPK nutrient sensing system can be activated
by the biguanide compound known as MET. MET has
been shown to induce a dietary restriction-like status and
oxidative stress response to extend lifespan in C. elegans
(15) and mice (16). METacts at least in part by triggering
AMPK and is a widely used drug for type 2 diabetes.
MET acts to reduce cellular ATP production by inhibit-
ing mitochondrial respiratory complex 1. This results in
activation of AMPK. In the liver, this results in reduced
gluconeogenesis, which reduces the hyperglycemia and
hyperinsulinemia of type 2 diabetes. The systemic affects
most likely reduce proliferation activity associated with
cancer, but direct effects on tumor cells may also be a
factor in reports of anticancer activity. For example,
pharmacoepidemiological evidence shows a 50% reduc-
tion in breast cancer risk in type 2 diabetic patients being
treated with MET for their diabetes (17).
The fourth system is BAR signaling. Physiological
stress responses are mediated through the release of
catecholamines epinephrine and norepinephrine. These
neurotransmitters are released from the adrenal medulla
as a response to emotional and physiological stress. In
addition, they regulate cell and organ response to the
sympathetic branch of the autonomic nervous system
(ANS) (18). They act by binding to adrenergic receptors,
which are a family of G-protein-coupled receptors that
initiate multiple cascades, including the adenyl cyclase/
cAMP/PKA pathway (19). BARs are receptors for epi-
nephrine and norepinephrine and part of the ANS. BARs
are expressed in multiple tissues to receive signals from
the ANS regarding fight-or-flight reactions, that is, stress.
The concept is that stress is associated with the devel-
opment and progression of chronic disease. Stress is
mediated by epinephrine or norepinephrine, which acti-
vate BAR’s on the cell surface of multiple tissues. This
triggers activation of cAMP and subsequently the protein
kinase A system, which stimulates cellular activation of
the transcription factor CREB, the EGFR pathway, the
Src/STAT pathway, BAR-mediated release of the ara-
chidonic acid cascade, and perpetuation of the stress
response. Stress is a major factor in reducing resistance to
such things as inflammation, tumor development, and
cardiovascular disease associated with increasing age.
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lation of PKA in mice has been shown to extend lifespan
and enhance healthy aging (2022).
The beta adrenergic signaling system can be inhibited
by antagonists referred to as beta blockers. PROP is a
beta blocker that has been used safely as a cardiovascular
therapeutic (mainly hypertension) for years (18). It also
has anti-anxiety affects. Recently, PROP has been shown
to reduce the proliferation, progression, angiogenesis and
metastasis of common epithelial cancers including breast,
prostate, lung, colon, and pancreas (19,23).
The QC theory of aging is referred to as a blue collar
theory because it can be tested by pharmacologically
targeting the four QC systems described above with a
combination of PBA, MET, and PROP. A critical aspect,
then, is that aging is associated with multiple cellular sys-
tems that can be targeted with drug combinations more
effectively than with single drugs. The QC theory of aging
provides a solid scientific rationale for the development
of a treatment strategy for aging and lifespan enhance-
ment that also serves as a means for treating and pre-
venting or delaying chronic age-related diseases. Therefore,
the potential impact should have huge implications for
pursuing treatment strategies for chronic diseases of
aging with a major paradigm shift from the development
of drugs specific for heart disease, diabetes, neurological
disease, cancer, and other diseases to the development
of synergistic drug combinations that delay aging and
prevent chronic diseases at the same time. Three drugs,
PBA, MET and PROP, can serve as a combination pro-
totype for the QC theory of aging to help establish why
we age and used as a platform to build on future analogs
and derivatives to improve combination drug efficiency
for aging intervention strategies.
Let us continue the discussion of this theory of aging
concept with submission of papers and letters to the
editor to Pathobiology of Aging & Age-related Diseases.
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